Rebuild America’s Health Care Schools Act of 2024

Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). Issues related to 340B program nondiscrimination and contract pharmacy arrangements (generally, no specific legislation). Issues related to manufacturer attempts to undercut the 340B program (generally, no specific legislation). Issues related to pharmacy residency funding, including support for the Rebuild Americas Health Care Schools Act of 2024 (S. 5397/H.R. 10225). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation).

Client expense: $220,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE

H.R. 1770, The Equitable Community Access to Pharmacist Services Act H.R. 2389, The Resident Physician Shortage Reduction Act of 2023 H.R. 5378, The Lower Costs, More Transparency Act; hospital outpatient department funding H.R. 7635, The 340B PATIENTS Act of 2024 H.R. 9351, The Save Our Safety-Net Hospitals Act of 2024 H.R. 9669/S.5091, The Basic Assistance for Students In College (BASIC) Act S. 4667, The Risky Research Review Act S. 5397/H.R. 10225, Rebuild Americas Health Care Schools Act of 2024 Hospital Inpatient Prospective Payment System (IPPS); funding for Graduate Medical Education (GME) resident physician slots H.R. 9029/S. 4942, FY 2025 Labor, Health and Human Services, Education and Related Agencies Appropriations Act; funding for the Children's Hospital Graduate Medical Education (GME) Program Medicaid Disproportionate Share Hospital (DSH) funding cut repeal related issues; extension of Medicare telehealth program related issues; issues related to Medicare Physician Fee Schedule related payment issues; Hospital Outpatient Prospective Payment System related issues Medicaid related issues

Client expense: $440,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Issues related to pharmacy benefit manager (PBM) abuses and transparency, including support for the following bills: the Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), the PBM Accountability Act (H.R. 2679), the Modernizing and Ensuring PBM Accountability Act (S. 2973), and the Pharmacy Benefit Manager Reform Act (S. 1339). Issues related to 340B program nondiscrimination and contract pharmacy arrangements, including support for the following bills: The PROTECT 340B Act (H.R. 2534) and the 340B Pharmaceutical Access to Invest in Essential, Needed Treatments & Support Act of 2024 (H.R. 7635). Issues related to manufacturer attempts to undercut the 340B program (generally, no specific legislation). Issues related to pharmacy residency funding, including support for the Rebuild Americas Health Care Schools Act of 2024 (S. 5397/H.R. 10225). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). The Biosimilar Red Tape Elimination Act (S. 2305) and the Affordable Prescriptions for Patients Act of 2023 (S. 150), issues related to accelerating biosimilar adoption.

Client expense: $210,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE